注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Gensight Biologics SA是一家法國的生物製藥公司。該公司開發並商業化基於基因療法的視網膜變性疾病的治療方法。它開發了一些方法來防止在選定的病理條件下視網膜變性並恢復視力低下或失明患者的視力。該公司主要計劃開發一種用於Leber遺傳性視神經病變(LHON)的基因替代療法和一種用於色素性視網膜炎(RP)的光遺傳療法。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Michael Stephen Wyzga | 66 | 2013 | Independent Chairman of the Board |
Jose-Alain Sahel | - | 2012 | Scientific Founder, Vice Chairman of Scientific Advisory Board & Board Observer |
Botond Roska | - | 2012 | Scientific Founder & Chairman of Scientific Advisory Board |
Serge Picaud | - | 2012 | Scientific Founder & Member of Scientific Advisory Board |
Constance L. Cepko | - | 2012 | Scientific Founder & Member of Scientific Advisory Board |
Luk H. Vandenberghe | - | 2012 | Scientific Founder & Member of Scientific Advisory Board |
Cédric Moreau | - | 2019 | Representative Director |
Maritza C. McIntyre | - | 2019 | Independent Director |
Laurence Rodriguez | - | 2023 | CEO & Director |
Simone Seiter | 57 | 2017 | Independent Director |
Ernst Bamberg | - | 2012 | Member of Scientific Advisory Board |
Elsy Lisa Boglioli | 42 | 2020 | Independent Director |
Francoise de Craecker | 61 | 2021 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核